Total Raised

$65.5M

Investors Count

25

Funding, Valuation & Revenue

20 Fundings

EpiBone has raised $65.5M over 20 rounds.

EpiBone's latest funding round was a Series A - II for $4.29M on October 24, 2025.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

10/24/2025

Series A - II

$4.29M

T.Rx Capital, and Zhu Ventures

$XXM

0

FY undefined

1

11/8/2024

Convertible Note - III

$XXM

0

FY undefined

1

9/11/2024

Convertible Note - II

$0.07M

$XXM

0

FY undefined

1

12/27/2022

Series A

$XXM

$XXM

0

FY undefined

10

11/26/2021

Unattributed - II

$XXM

$XXM

0

FY undefined

10

Date

10/24/2025

11/8/2024

9/11/2024

12/27/2022

11/26/2021

Round

Series A - II

Convertible Note - III

Convertible Note - II

Series A

Unattributed - II

Amount

$4.29M

$0.07M

$XXM

$XXM

Investors

T.Rx Capital, and Zhu Ventures

Valuation

$XXM

$XXM

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

1

1

10

10

Start free trial
New call-to-action

EpiBone Investors

25 Investors

EpiBone has 25 investors. Zhu Ventures invested in EpiBone's Series A - II funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

10/24/2025

10/24/2025

Zhu Ventures
1
Series A - II

Venture Capital

California

10/24/2025

10/24/2025

1
Series A - II

Venture Capital

Massachusetts

11/26/2021

11/8/2024

2
Unattributed - II, Convertible Note - III (2024)

Venture Capital

United Kingdom

00/00/0000

00/00/0000

LifeSpan Vision Ventures

Subscribe to see more

Venture Capital

Connecticut

00/00/0000

00/00/0000

Kendall Capital Partners

Subscribe to see more

First funding

10/24/2025

10/24/2025

11/26/2021

00/00/0000

00/00/0000

Last Funding

10/24/2025

10/24/2025

11/8/2024

00/00/0000

00/00/0000

Investor

Zhu Ventures

LifeSpan Vision Ventures

Kendall Capital Partners

Rounds

1
Series A - II
1
Series A - II
2
Unattributed - II, Convertible Note - III (2024)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Venture Capital

Venture Capital

Venture Capital

Location

California

Massachusetts

United Kingdom

Connecticut

New call-to-action

Compare EpiBone to Competitors

R
Regeneus

Regeneus is a company focused on providing analysis of air freight operations within the logistics and transportation sector. Its main offerings include insights into the handling of urgent air cargo, the decision-making processes involved, and the operational realities of Australia's air freight network under time-critical conditions. The company serves sectors that require shipping solutions, such as medical, humanitarian, and critical component industries. It is based in Paddington, New South Wales.

B
BioLab Sciences

BioLab Sciences is a company involved in regenerative medicine and advanced wound care within the healthcare sector. They provide products such as membrane wraps and protective coverings. The company serves the medical and healthcare industry. It is based in Scottsdale, Arizona.

DiscGenics Logo
DiscGenics

DiscGenics is a clinical stage biopharmaceutical company engaged in the development of cell-based therapies within the healthcare industry. The company's offerings include injectable cell therapies aimed at alleviating pain and restoring function for patients with degenerative diseases of the spine, particularly lumbar disc degeneration. DiscGenics serves the healthcare sector, primarily addressing conditions associated with chronic back pain. It was founded in 2007 and is based in Salt Lake City, Utah.

Novadip Biosciences Logo
Novadip Biosciences

Novadip Biosciences is a clinical-stage biopharmaceutical company involved in developing regenerative tissue products within the bone and tissue regenerative medicine sector. The company provides treatments for conditions such as large bone defects, bone non-union, and spinal fusion. Novadip's products include the allogeneic NVD-X3 and the autologous NVD-003. It was founded in 2013 and is based in Mont-Saint-Guibert, Belgium.

V
Videregen

Videregen offers a commercially available organ replacement product to address the chronic shortage of organs for transplantation. Formed in 2011 as a spin-out from Northwick Park Institute of Medical Research in London, it uses its proprietary technology to produce biological scaffolds to which a patient's own stem cells are added, creating a bespoke organ replacement.

N
Novo Biosciences

Novo Biosciences is a biotechnology company focused on pioneering new therapies in regenerative medicine. The company's main offerings include the development of breakthrough drugs designed to regenerate damaged organs and tissues by activating the body's inherent self-repair mechanisms. Novo Biosciences primarily targets the medical healthcare sector with its innovative pharmacotherapies. It was founded in 2013 and is based in Bar Harbor, Maine.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.